These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 11021828)
21. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis. Bhutani D; Leng S; Lentzsch S Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. O'Nuallain B; Hrncic R; Wall JS; Weiss DT; Solomon A J Immunol; 2006 Jun; 176(11):7071-8. PubMed ID: 16709869 [TBL] [Abstract][Full Text] [Related]
23. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis. Wang J; Li J; Zhong L Blood Rev; 2024 Jul; 66():101207. PubMed ID: 38692939 [TBL] [Abstract][Full Text] [Related]
24. Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils. Phay M; Blinder V; Macy S; Greene MJ; Wooliver DC; Liu W; Planas A; Walsh DM; Connors LH; Primmer SR; Planque SA; Paul S; O'Nuallain B Rejuvenation Res; 2014 Apr; 17(2):97-104. PubMed ID: 24164623 [TBL] [Abstract][Full Text] [Related]
25. Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses. Zhang X; Sun XX; Xue D; Liu DG; Hu XY; Zhao M; Yang SG; Yang Y; Xia YJ; Wang Y; Liu RT Biochim Biophys Acta; 2011 Dec; 1814(12):1703-12. PubMed ID: 21979582 [TBL] [Abstract][Full Text] [Related]
26. Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion. Foster JS; Balachandran M; Hancock TJ; Martin EB; Macy S; Wooliver C; Richey T; Stuckey A; Williams AD; Jackson JW; Kennel SJ; Wall JS Front Immunol; 2023; 14():1275372. PubMed ID: 37854603 [TBL] [Abstract][Full Text] [Related]
27. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348 [TBL] [Abstract][Full Text] [Related]
28. A Substantial Structural Conversion of the Native Monomer Leads to in-Register Parallel Amyloid Fibril Formation in Light-Chain Amyloidosis. Lecoq L; Wiegand T; Rodriguez-Alvarez FJ; Cadalbert R; Herrera GA; Del Pozo-Yauner L; Meier BH; Böckmann A Chembiochem; 2019 Apr; 20(8):1027-1031. PubMed ID: 30565364 [TBL] [Abstract][Full Text] [Related]
29. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Edwards CV; Rao N; Bhutani D; Mapara M; Radhakrishnan J; Shames S; Maurer MS; Leng S; Solomon A; Lentzsch S; Eisenberger A Blood; 2021 Dec; 138(25):2632-2641. PubMed ID: 34521113 [TBL] [Abstract][Full Text] [Related]
30. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis. Fujimoto N; Yajima M; Ohnishi Y; Tajima S; Ishibashi A; Hata Y; Enomoto U; Konohana I; Wachi H; Seyama Y J Invest Dermatol; 2002 Mar; 118(3):479-84. PubMed ID: 11874487 [TBL] [Abstract][Full Text] [Related]
31. Localized laryngeal amyloidosis: partial characterization of an amyloid fibril protein AL. Westermark P; Sletten K; Pitkänen P; Natvig JB; Lindholm CE Mol Immunol; 1982 Mar; 19(3):447-50. PubMed ID: 6808355 [TBL] [Abstract][Full Text] [Related]
32. Lambda II immunoglobulin light chain protein in primary localized rectal amyloidosis. Zaky ZS; Liepnieks JJ; Rex DK; Cummings OW; Benson MD Amyloid; 2007 Dec; 14(4):299-304. PubMed ID: 17968691 [TBL] [Abstract][Full Text] [Related]
33. The pattern of amyloid deposition in the lung. Looi LM Malays J Pathol; 1999 Jun; 21(1):29-35. PubMed ID: 10879276 [TBL] [Abstract][Full Text] [Related]
34. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. Ren R; Hong Z; Gong H; Laporte K; Skinner M; Seldin DC; Costello CE; Connors LH; Trinkaus-Randall V J Biol Chem; 2010 Nov; 285(48):37672-82. PubMed ID: 20870723 [TBL] [Abstract][Full Text] [Related]
35. Light chain amyloidosis - current findings and future prospects. Baden EM; Sikkink LA; Ramirez-Alvarado M Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145 [TBL] [Abstract][Full Text] [Related]
36. Nodular pulmonary immunoglobulin light chain deposits with coexistent amyloid and nonamyloid features in an HIV-infected patient. Stokes MB; Jagirdar J; Burchstin O; Kornacki S; Kumar A; Gallo G Mod Pathol; 1997 Oct; 10(10):1059-65. PubMed ID: 9346188 [TBL] [Abstract][Full Text] [Related]
37. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. Enqvist S; Sletten K; Stevens FJ; Hellman U; Westermark P PLoS One; 2007 Oct; 2(10):e981. PubMed ID: 17912358 [TBL] [Abstract][Full Text] [Related]
38. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Wall JS; Kennel SJ; Stuckey AC; Long MJ; Townsend DW; Smith GT; Wells KJ; Fu Y; Stabin MG; Weiss DT; Solomon A Blood; 2010 Sep; 116(13):2241-4. PubMed ID: 20522711 [TBL] [Abstract][Full Text] [Related]
39. Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils. Skaat H; Corem-Slakmon E; Grinberg I; Last D; Goez D; Mardor Y; Margel S Int J Nanomedicine; 2013; 8():4063-76. PubMed ID: 24194640 [TBL] [Abstract][Full Text] [Related]